canertinib has been researched along with rottlerin in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (rottlerin) | Trials (rottlerin) | Recent Studies (post-2010) (rottlerin) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 556 | 1 | 202 |
| Protein | Taxonomy | canertinib (IC50) | rottlerin (IC50) |
|---|---|---|---|
| Eukaryotic elongation factor 2 kinase | Homo sapiens (human) | 5.3 | |
| B2 bradykinin receptor | Cavia porcellus (domestic guinea pig) | 1.2 | |
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | 8 | |
| Beta-lactamase | Escherichia coli K-12 | 1.5 | |
| Malate dehydrogenase | Thermus thermophilus | 0.7 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2 | |
| MAP kinase-activated protein kinase 2 | Homo sapiens (human) | 5.4 | |
| Protein kinase C delta type | Homo sapiens (human) | 3 | |
| MAP kinase-activated protein kinase 5 | Homo sapiens (human) | 1.9 | |
| WD repeat-containing protein 48 | Homo sapiens (human) | 8 | |
| RuvB-like 1 | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for canertinib and rottlerin
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |